Starting in 1998, The Psoriasis Treatment Center of Central New Jersey participated in clinical trials with Amevive (alefacept; Astellas Pharma). Over 50 patients who had not attained a prolonged remission with phototherapy participated in these trials. On January 31, 2003, Amevive became the first biologic agent to be FDA approved for the treatment of moderate-to-severe psoriasis.
Subsequently, The Psoriasis Treatment Center of Central New Jersey participated in clinical trials with other biologic agents:
- Enbrel (etanercept; Amgen-Wyeth/Pfizer) starting in 1999
- Raptiva (efalizumab; Genentech) in 2000
- Stelara (ustekinumab; Centocor Ortho Biotech) in 2005
- Humira (adalimumab; Abbott Labs) in 2006
- ABT-874 (Abbott Labs) in 2007
Our mission has been to offer clinical trials to people with psoriasis who have previously failed already FDA-approved therapies.
No comments:
Post a Comment